Skip to main content
. 2020 Sep 2;7:497. doi: 10.3389/fmed.2020.00497

Table 2.

Review of the literature regarding PSP of the lung.

Author/year Patients enrolled (n) Gender (M/F) Age (Mean) Type of treatment IHC marker Methastatic lymphonodes Recurrence
Hu et al. (26) 46 5 M 41 F 51.4 45/46 Surgery
−21 enucleation
−9 wedge resections −15 lobectomies
/ / No
Devouassoux- Shisheboran et al. (18) 100 17 M 83 F 46 54/100 Surgery:
5 wedge resections
37 lobectomies
2 bilobectomies
1 pneumonectomy
- 9 procedures not specified specificata
-pancytokeratin+; CAM 5.2+, CK7 +, EMA + calretinin –; CK5/6 –
TTF1 +; Sp A e B + chromogranin –; synaptophysin –; Leu 7 –
- S100 -
Yes, 1 case No
Shin et al. (27) 76 9 M
67 F
50 45/76 Surgery:
33 segmentectomies
11 lobectomies
- 1 bilobectomies
TTF1+, cytokeratin +, EMA+;
- ki-67–
/ /
Yang et al. (28) 59 2 M
57 F
49.85 Wedge resection (58 wedge resections) Surface cell AE1/AE3+ e CK7+;
Stromal cell AE1/AE3- e CK7+;
- TTF1+ e EMA+
No No
Lei et al. (29) 28 3 M
25 F
46.1 13 enucleation
7 wedge resection
8 lobectomies
/ No Yes
Park et al. (30) 32 1 M
31 F
47.8 19 lobectomies
5 wedge resections
1 segmentectomy
7 wedge resections
/ Yes, 1 case No
Cho et al. (31) 11 1 M
10 F
48.6 Surgery MMP-9 +
Tubulinα +
IGF1 +
/ /
Schmidt (32) 6 / / / TTF1 +
Napsin A +
/ /
Wu et al. (33) 18 2 M
16 F
44.6 / P40 +
TTF1+, SHL+, EMA+, Vimentin+
No No
Lovrenski et al. (34) 6 1 M
5 F
/ Surgery TTF1+ e panCK + No No

This Table shows treatments and immunohistochemical characteristics. ALDH and SOX-2 have been never considered.